IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
Biotron is a Public Company that generates the majority of its income from the Pharmaceutical Product Manufacturing industry. In 2025 the company generated total revenue of $35,000 including sales and other revenue. The exact number of employees for this organisation is not available. The Chief Executive of Biotron is Dr Michelle Miller whose official title is Chief Executive Officer & Managing Director. The Chairman of Biotron is Mr Michael Hoy whose official title is Independent Non-Executive Chairman. Biotron Limited is a biotechnology company, engaged in research and development projects. The company’s lead antiviral drug is BIT225, which is in mid-stage clinical development for treatment of HIV-1 and HCV. The company also has a portfolio of preclinical antiviral programs that develop drugs, targeting viral diseases such as: Influenza Dengue virus Zika Virus Ebola and SARs
IBISWorld's research coverage of Biotron Limited includes financial statements, operating segments, competitor benchmarking, key personnel and shareholders.
Biotron Limited, trading as Biotron, operates under the ABN 60 086 399 144 and was incorporated on 23 February 1999. Biotron Limited trades on the Australian Securities Exchange under the ticker code ASX:BIT. Biotron Limited primarily operates in Pharmaceutical Product Manufacturing and Scientific Research Services industries in Australia.
The Key Personnel chapter outlines the principal leadership positions within Biotron Limited, including the Chairman, Board members, Chief Executive Officer, and other key management personnel. It provides an overview of the company’s governance and executive structure, along with a breakdown of gender diversity across leadership roles, offering insight into the composition of the organisation’s senior team.
The Financials chapter presents Biotron Limited’s historical financial performance, including detailed profit and loss statements outlining sales revenue, cost of sales, and profitability. It also incorporates balance sheet data, providing a breakdown of assets and liabilities, as well as additional financial metrics such as the number of shares on issue. Together, these disclosures offer a comprehensive view of the company’s financial position and performance over time.
The Growth & Ratios chapter provides historical data on key financial performance indicators, enabling an assessment of the company’s operational efficiency, profitability, and financial structure over time. Metrics covered include return on equity, return on assets, profit margins, revenue per employee, as well as gearing and leverage ratios, offering a comprehensive view of performance trends and capital management.
The Operating Segments chapter provides an overview of the revenue composition and asset allocation across the various industries in which Biotron Limited operates. It offers insights into how the company’s financial performance is distributed among its core business segments, highlighting the relative contribution of each industry to total revenue.
The Competitor Benchmarking chapter includes a comparative assessment of Biotron Limited’s key financial, growth, and valuation ratios against industry averages to evaluate its competitive position. It analyses valuation metrics such as price-to-earnings, price-to-book, enterprise value to EBITDA, and enterprise value to sales, alongside core financial indicators including liquidity ratios and profitability measures.
The Industries of Operation chapter outlines Biotron Limited’s market share across the industries in which it operates. Each industry profile includes a comprehensive overview featuring data on total market size, the number of enterprises, industry concentration levels, and overall turnover. This analysis provides context for the company’s competitive position and scale within each relevant market.
The Shareholders chapter provides a breakdown of the ownership structure of Biotron Limited, identifying key shareholders and outlining their respective ownership interests. This section offers insight into the concentration of shareholdings, the presence of institutional or strategic investors, and the overall distribution of equity within the company.
The Subsidiaries chapter provides an overview of the companies and business entities that are wholly or partially owned by Biotron Limited. It outlines the ownership structure of each subsidiary, offering insight into the broader corporate group and how these entities contribute to the company’s overall activities and performance.
The History chapter presents a overview of Biotron Limited’s development, highlighting key milestones and significant corporate events since its incorporation. It includes the company’s incorporation date and outlines major strategic, operational, and structural developments, providing context for its evolution and current market position.
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
Biotron Limited is a biotechnology company, engaged in research and development projects. The company’s lead antiviral drug is BIT225, which is in mid-stage clinical development for treatment of HIV-1 and HCV. The company also has a portfolio of preclinical antiviral programs that develop drugs, targeting viral diseases such as: Influenza Dengue virus Zika Virus Ebola and SARs
Biotron Limited, trading as Biotron, is a Public Company that generates the majority of its income from the Pharmaceutical Product Manufacturing industry in Australia.
Biotron Limited company is based at 66 Hunter Street, Sydney, New South Wales, Australia.
The FINANCIAL DECISION MAKER of Biotron Limited is Peter James Nightingale and the MANAGING DIRECTOR is Michelle Miller.
In 2025, Biotron Limited generated total revenue of approximately $35.0 thousand.